Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Bavarian Nordic tiene un patrimonio de accionistas total de DKK10.3B y una deuda total de DKK17.0M, lo que sitúa su ratio deuda-patrimonio en 0.2%. Sus activos y pasivos totales son DKK14.4B y DKK4.0B respectivamente. El BAIT de Bavarian Nordic es de DKK2.2B, por lo que su ratio de cobertura de intereses es de -42.8. Tiene efectivo e inversiones a corto plazo que ascienden a DKK1.9B.

Información clave

0.2%

Ratio deuda-patrimonio

kr.16.58m

Deuda

Ratio de cobertura de intereses	-34.9x
Efectivo	kr.2.29b
Patrimonio	kr.10.17b
Total pasivo	kr.3.45b
Activos totales	kr.13.62b

Actualizaciones recientes sobre salud financiera

Recent updates

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Jul 24

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Jun 14

Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)

May 31

Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?

May 06

Bavarian Nordic A/S (CPH:BAVA) Analysts Just Cut Their EPS Forecasts Substantially

Mar 13

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK5.4B) de BAVA superan a sus pasivos a corto plazo (DKK2.8B).

Pasivo a largo plazo: Los activos a corto plazo de BAVA (DKK5.4B) superan a sus pasivos a largo plazo (DKK1.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BAVA tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de BAVA ha pasado de 29.7% a 0.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de BAVA está bien cubierta por el flujo de caja operativo (6565%).

Cobertura de intereses: BAVA gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de Bavarian Nordic

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?

Recent updates

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to kr.418

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Consensus forecasts updated

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Price target increased to kr.390

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Consensus estimates of losses per share improve by 21%

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Consensus revenue estimates increase by 13%

Consensus forecasts updated

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)

First quarter 2022 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022